Nitric oxide deficiency occurs by multiple mechanisms and contributes to the pathogenesis of progression of chronic kidney disease (CKD) and its cardiovascular complications. This article concentrates on recent developments on the regulation of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) in CKD and on the importance of the nitric oxide synthases in kidney disease progression, particularly in diabetic nephropathy.
INTRODUCTION
In animal studies, experimentally induced chronic nitric oxide synthase (NOS) inhibition causes systemic and glomerular hypertension, glomerular ischemia, glomerulosclerosis, tubulointerstitial injury and proteinuria [1, 2] . There is also considerable clinical and experimental evidence that nitric oxide deficiency develops as a result of chronic kidney disease (CKD) and that nitric oxide deficiency is linked to progression of renal dysfunction [1] [2] [3] [4] .
Nitric oxide acts locally, therefore the location of the nitric oxide deficiency dictates the pathology. Widespread vascular endothelial nitric oxide deficiency (endothelial dysfunction) occurs throughout the course of CKD and contributes to the increased risk of adverse cardiovascular events [3] . In addition, animal studies implicate intrarenal nitric oxide deficiency in the pathogenesis of CKD progression [1] . In support of a key role for nitric oxide deficiency in the pathogenesis of renal disease, nitric oxide repletion by administration of nitrite (NO 2 ) or nitrate (NO 3 ) reduced blood pressure (BP) and greatly retarded progression of CKD in two rat models of hypertension and kidney damage [5,6 && ]. The high dietary content of NO 3 in vegetables and fruit may contribute to the cardiovascular protection afforded by these foods [7] .
There are several potential mechanisms by which nitric oxide deficiency could occur in CKD and in this review we consider recent research on the endogenous NOS inhibitors which compete with
ENDOGENOUS NITRIC OXIDE SYNTHASE INHIBITORS
Asymmetric dimethylarginine (ADMA) is an endogenous NOS inhibitor recognized as a major cardiovascular risk factor [8] . Even within the 'normal' population, those with plasma ADMA in the upper range of normal are at increased risk for adverse cardiovascular events. Elevations in plasma ADMA are seen in many pathologies including renal disease, and individuals in the upper range have the worst outcome [8] . As a note of caution, whereas a high plasma ADMA probably represents an elevation in intracellular ADMA, the relationship between circulating and tissue levels of ADMA is not straightforward and will likely vary for different tissues [8, 9] .
Asymmetric dimethylarginine is a difficult molecule to measure and a number of HPLC, gas chromatography-mass spectrometry and recently ELISA methods have been used, resulting in variability in the values considered 'normal' and in those seen in renal disease [1, 8, [10] [11] [12] [13] . Plasma ADMA can be very high in end-stage kidney disease (ESKD) and is variable, even within a defined population, with the cardiovascular risk being exacerbated when plasma ADMA is greater than the 50% percentile [8, 10] . In CKD plasma ADMA is very variable and reported as unchanged in some patients, increased mildly or markedly without correlation to the severity of CKD, and increased in proportion to the severity of CKD [1, 13] . In stage 1, nondiabetic CKD and stage 1 IgA nephropathy patients, in whom glomerular filtration rate (GFR) is normal, the plasma ADMA correlated with proteinuria [14,15 & ], whereas in the 'Modification of Diet in Renal Disease' population of predominantly nondiabetic stage 3-4 CKD patients, high plasma ADMA correlated with low GFR but not proteinuria [16] . In recent studies from Taiwan ($50% diabetic, stage 3-4 CKD) and Norway (predominantly nondiabetic, stage 1-5 CKD) an inverse relationship was reported between plasma ADMA and creatinine [17 & ,18] . In general the highest plasma ADMA was associated with rapid CKD progression [15 & ,19,20] ] recently reported a gain-of-function polymorphism in the DDAH1 gene, associated with reduced plasma ADMA in both normal individuals and individuals with CKD. Rather than being protective, however, the genotype conferring lower plasma ADMA was associated with a more rapid rate of CKD progression in two separate populations [21 & ]. This serves as a reminder that there are many unknown factors determining CKD progression.
The loss of renal clearance in renal failure causes plasma ADMA to increase although relatively little ADMA is excreted unchanged in the urine, approximately 15-20% in normal humans. Whereas we should not ignore the importance of renal clearance, the increase in plasma ADMA in stage 1 CKD [1,14,15 & ] implicates additional causes. Enzymatic degradation of ADMA by dimethylarginine dimethylaminohydrolase, DDAH1 and 2, provides the majority of ADMA removal and DDAH is widely distributed and most abundant in the kidney, and also liver and vascular endothelium [11] . DDAH cosegregates with NOS, and DDAH1 is predominantly located in neuronal and epithelial tissues with neuronal (n)NOS and is abundant in kidney and liver. DDAH2 is found predominantly in the vasculature, in association with endothelial (e)NOS, although there is overlap in the distribution of the isoforms [11] . The activity of DDAH clearly influences nitric oxide generation and cardiovascular function, via control of ADMA [1, [9] [10] [11] 22, 23] .
It is widely held that renal and hepatic DDAH1 activity controls plasma ADMA, whereas DDAH2 regulates vascular tissue ADMA and hence vascular tone, without influencing plasma ADMA [1, 11] , although recent gene manipulation studies have raised some questions. Global DDAH1 overexpression causes enhanced vascular and cardiac DDAH activity vs. wild-type but without any increase in renal or hepatic DDAH activities [24] . Nevertheless, plasma ADMA and BP fall, implicating a role for
KEY POINTS
Dietary nitrate supplementation may provide a novel and economic treatment for kidney and cardiovascular disease.
Whereas plasma asymmetric dimethylarginine (ADMA) predicts cardiovascular risk in chronic kidney disease (CKD), the role of the kidney damage in the elevation and the variability of plasma ADMA remains unclear.
The relative importance of the two dimethylarginine dimethylaminohydrolase isoforms in regulation of ADMA is controversial.
Nitric oxide deficiency due to loss of eNOS activity plays a key role in development of diabetic nephropathy.
The possible pathogenic role of the nNOSb isoform in mediation of CKD progression is under investigation.
increased cardiovascular DDAH activity in plasma ADMA control in these mice. Selective endothelial DDAH1 knockout also causes increased plasma ADMA and BP with falls in nitric oxide-dependent vascular responses [25] . Thus, vascular DDAH1 can take over as a prime controller of plasma ADMA and vascular tone.
The ]. Thus, the relative importance of DDAH1 and 2 in the clearance of ADMA remains to be determined.
Some of the new information, discussed above, questions the dogma that plasma ADMA is primarily controlled by renal and hepatic uptake and metabolism. In addition to the transgenic mice studies [24, 25] in which endothelial DDAH activity controls plasma ADMA, plasma ADMA falls in normal individuals after acute uninephrectomy for kidney donation [31 & ], and a similar observation was reported in the rat [32] after total nephrectomy. There is no clear mechanism for the fall in plasma ADMA immediately post-nephrectomy although the acute inflammatory response to the surgery may be involved [31 & ]. Whatever the explanation it is clear that renal and hepatic DDAH activities are not the only controllers of plasma ADMA. Thus, whereas there is interest in exploring the therapeutic potential of boosting 'in-vivo' DDAH activity [22] , the DDAH isoform and organ(s) to be targeted remain to be determined.
In addition to enzyme abundance the activity of the DDAH enzymes will play a role in regulation of ADMA levels. There is not a great deal known about post-translational regulation of DDAH activity but it is clear that oxidative stress inhibits DDAH transcription and activity [11] and that inflammation and oxidative stress are evident in CKD, even when only mild renal insufficiency is present [1, 33] . Earlier in-vitro work suggested that oxidative stress is also associated with enhancement of ADMA synthesis via stimulation of protein methyltransferase 1 (PRMT1) [34, 35] . There has been a lull in research in this important area but the relationship between reactive oxygen species (ROS) and ADMA levels in CKD/ESKD merits further exploration. Of considerable potential therapeutic interest, dietary NO 3 supplementation in a hypertensive salt-dependent model of CKD prevented oxidative stress and restored the elevated ADMA to normal [6 && ]. With regard to oxidative stress in CKD and hypertension, we know that this results from an imbalance between oxygen radical production and removal; however, specific causes of oxidative stress are many and varied [36] . One source of ROS is via stimulation of NADPH-dependent superoxide generation due to increased angiotensin II activity in the damaged kidney. There are a variety of other oxidases that can also generate ROS (e.g. xanthine oxidase, cyclooxygenases, uncoupled NOS, etc.), although NADPH oxidase is thought to be the most important renal oxidase. In addition to excessive ROS generation, oxidative stress can develop due to failure of the antioxidant systems such as the superoxide dismutases that convert superoxide to H 2 O 2 or the downstream enzymes such as catalase or glutathione that get rid of the H 2 O 2 [36] . In ESKD, HDL falls and what is left loses its ability to inhibit oxidation of lipids and lipoproteins [37] ; then there are the prooxidant 'uremic toxins' [33] . The location of generation of ROS is also critical since ROS act locally and are scavenged or enzymatically removed very quickly. So superoxide arising in mitochondria will have a different impact to cytosolic or extracellular superoxide and ROS made in an infiltrating macrophage will have a different action to ROS generated in a vascular smooth muscle cell.
Therefore, there are probably many types/causes of oxidative stress that occur in CKD and hypertension which can have a wide variety of impacts. In addition to stimulation of ADMA levels by both increased PRMT1 and decreased DDAH activities [1, 11, 34, 35] , ROS have many other effects on nitric oxide bioavailability. For example superoxide reacts with and inactivates nitric oxide and also oxidizes tetrahydrobiopterin which is essential for NOS activity and converts the NOS to superoxide generators [36] , thus creating a vicious cycle. Also, oxidative stress leads to inflammation which leads to arginase induction which may also reduce arginine, and thence nitric oxide availability [36, 38, 39] .
ARGININE AVAILABILITY
Whereas there has been extensive study of aspects of ADMA metabolism in renal disease, there has been little recent investigation into arginine availability, which is surprising since the normal kidney synthesizes the majority of the arginine in the circulation [40, 41] . The impact of renal disease on the ability of the kidney to produce arginine is controversial [39] , although we recently reported that loss of the renal cortical arginosuccinate synthase and lyase enzymes occurs early and persists through the course of experimentally induced CKD [42 & ]. This results in a marked fall in renal arginine release into the circulation, despite which plasma arginine remains at normal values [42 & ]. Normal plasma arginine is routinely seen in renal failure patients and animals and we have suggested that the 'normal' plasma arginine level camouflages an intracellular arginine deficiency and that plasma arginine levels are maintained because endothelial arginine uptake from plasma is impaired [1, 39] . This is due both to the presence of circulating inhibitors of the arginine transporters and to reduction in transporter abundance/activity in blood vessels from rats with experimentally induced CKD and age-dependent nephropathy [1, 39, 43, 44] . Further studies on other CKD models and in humans would be helpful in evaluating the arginine status in renal disease.
NITRIC OXIDE SYNTHASE PROTEINS
In addition to ADMA and arginine levels, the location, abundance and activity of the various NOSs are critical in determining nitric oxide production. As well as producing de-novo hypertension and CKD, chronic pharmacologic nonselective NOS inhibition promotes CKD progression in otherwise resistant strains such as the Wistar Furth and spontaneously hypertensive rat (SHR) [1, 4] . The C57Bl6 mouse is also resistant to renal mass reductioninduced CKD and we recently reported that chronic, nonselective NOS inhibition greatly exacerbated CKD progression [45] .
As discussed above, the vascular endothelium develops nitric oxide deficiency in CKD. There are no eNOS-selective NOS inhibitors but a number of recent studies in the eNOS knockout mouse have yielded novel insights, in particular with regard to diabetic nephropathy. The C57Bl6 mouse is resistant to the development of diabetic nephropathy but the eNOS knockout develops nephropathy in response to induction of type 1 diabetes with streptozotocin [46, 47] . Furthermore, crossing the eNOS knockout with the type 2 diabetic db/db mouse amplifies the renal injury [48, 49] and both type 1 and type 2 mice develop the histological features of advanced human diabetic nephropathy. Recent work suggests that whereas both angiotensin-converting enzyme (ACE) inhibition (ACEI) and angiotensin receptor blockade (ARB) effectively prevented both glomerular and tubulointerstitial diabetic injury in wild-types, the type 1 diabetic eNOS knockouts were much less responsive [50 & ], suggesting that eNOS-derived nitric oxide is required for the full therapeutic response to angiotensin blockers. When the eNOSþ/À mouse is crossed with the Akita model of spontaneous type 1 diabetes there is also amplification of the diabetic nephropathy [51] . These mice resemble the pattern seen in diabetic patients with putative 'loss-of-function' eNOS polymorphisms [52] [53] [54] . A lack or deficiency of eNOS-derived nitric oxide within the kidney will provoke both glomerular and peritubular capillary injury leading to tubulointerstitial damage and exacerbating the damaging effects of hyperglycemia [55] .
We have also reported that the renal cortical nNOS abundance and activity fall in multiple rat models of CKD [1] . In the renal ablation/infarction model there is a linear relationship between loss of cortical nNOS and progression of glomerular damage. The Wistar Furth male and Sprague-Dawley female rats are both resistant to CKD and maintain renal cortical nNOS abundance after an insult to the kidney [1] . The CKD-resistant C57Bl6 mouse is rendered vulnerable to CKD by both nonselective NOS inhibition and 'selective' nNOS inhibition [45] .
These observations have focused us on the kidney cortex nNOS in the pathogenesis of CKD progression. We recently reported the existence of a splice variant of nNOS, the truncated nNOSb, in the rat kidney cortex [56] . This is a fully active enzyme which lacks the unique amino-terminus of the nNOSa and is located in the cytosol. Under normal conditions nNOSb is present in low abundance but as nNOSa abundance declines during CKD progression, the nNOSb increases in several rat models of CKD [56] [57] [58] . This is unlikely to be a compensatory response since the increased nNOSb in the 5/6AI KC does not replace the nNOSa in location or function [1, 57] . We also recently reported that the senescent Fisher 344/Brown Norway cross, which develops very mild glomerular damage, exhibits increases in nNOSb before any falls in nNOSa [59] . We are currently investigating whether the increased nNOSb may play a causal role in the injury development.
CONCLUSION
There is strong evidence that increased ADMA contributes both to CKD progression and to the elevated cardiovascular risk. There are some indications that vascular DDAH activity may play an important role in control of plasma ADMA and can perhaps compensate in some individuals when the kidney is damaged. The relative importance of the two DDAH isoforms in ADMA regulation remains uncertain and must be determined in order to optimize drug targeting.
Alterations in NOS also influence CKD progression and eNOS deficiency is particularly involved in the pathogenesis of diabetic nephropathy. The use of dietary NO 3 supplements to restore normal nitric oxide and oxidant status provides a novel and simple therapeutic option for CKD. This study on a novel transgenic mouse with global DDAH1 knockout has several important messages. First, that DDAH1 is not required for embryonic development, as originally reported [23] . Also that in the baseline state these mice have an unexpectedly mild cardiovascular phenotype. Finally, that despite substantial levels of DDAH2 protein, residual DDAH activity in the DDAH1 knockout was negligible, suggesting a minimal functional role for DDAH2 in ADMA metabolism. First study on DDAH polymorphisms in type 2 diabetic patients, reveals five single nucleotide polymorphisms in DDAH1 gene associated with plasma ADMA level, mainly in those patients without diabetic retinopathy. One DDAH2 associated SNP that correlated with plasma ADMA was also reported although this was not within the DDAH2 gene but within the block of linkage disequilibrium. There was also evidence of an interaction between the DDAH1 and 2 genes on plasma ADMA. 
